• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BRCA1与乳腺癌:分子机制及治疗策略

BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.

作者信息

Fu Xiaoyu, Tan Wei, Song Qibin, Pei Huadong, Li Juanjuan

机构信息

Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.

出版信息

Front Cell Dev Biol. 2022 Mar 1;10:813457. doi: 10.3389/fcell.2022.813457. eCollection 2022.

DOI:10.3389/fcell.2022.813457
PMID:35300412
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8921524/
Abstract

Breast cancer susceptibility gene 1 () is a tumor suppressor gene, which is mainly involved in the repair of DNA damage, cell cycle regulation, maintenance of genome stability, and other important physiological processes. Mutations or defects in the gene significantly increase the risk of breast, ovarian, prostate, and other cancers in carriers. In this review, we summarized the molecular functions and regulation of and discussed recent insights into the detection and treatment of mutated breast cancer.

摘要

乳腺癌易感基因1()是一种肿瘤抑制基因,主要参与DNA损伤修复、细胞周期调控、基因组稳定性维持等重要生理过程。该基因的突变或缺陷会显著增加携带者患乳腺癌、卵巢癌、前列腺癌等其他癌症的风险。在这篇综述中,我们总结了该基因的分子功能和调控,并讨论了近年来对该基因突变型乳腺癌检测与治疗的新见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6beb/8921524/5e6efb32c2f7/fcell-10-813457-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6beb/8921524/0c8f04fbc88f/fcell-10-813457-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6beb/8921524/5e6efb32c2f7/fcell-10-813457-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6beb/8921524/0c8f04fbc88f/fcell-10-813457-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6beb/8921524/5e6efb32c2f7/fcell-10-813457-g002.jpg

相似文献

1
BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.BRCA1与乳腺癌:分子机制及治疗策略
Front Cell Dev Biol. 2022 Mar 1;10:813457. doi: 10.3389/fcell.2022.813457. eCollection 2022.
2
BRCA1 gene in breast cancer.乳腺癌中的BRCA1基因。
J Cell Physiol. 2003 Jul;196(1):19-41. doi: 10.1002/jcp.10257.
3
BRCA1 in the DNA damage response and at telomeres.BRCA1 在 DNA 损伤反应和端粒中。
Front Genet. 2013 Jun 21;4:85. doi: 10.3389/fgene.2013.00085. eCollection 2013.
4
BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer.BRCA1及其易损的C端BRCT结构域:结构、功能、基因突变以及与乳腺癌和卵巢癌诊断与治疗的关联
Pharmaceuticals (Basel). 2024 Mar 4;17(3):333. doi: 10.3390/ph17030333.
5
Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.乳腺癌1号基因(BRCA1)和共济失调毛细血管扩张症突变基因(ATM)的突变对细胞对电离辐射反应的不同影响。
Int J Radiat Biol. 2003 Oct;79(10):817-29. doi: 10.1080/09553000310001610952.
6
BRCA1 and prostate cancer.乳腺癌1号基因(BRCA1)与前列腺癌
Cancer Invest. 2001;19(4):396-412. doi: 10.1081/cnv-100103134.
7
BRCA1, a 'complex' protein involved in the maintenance of genomic stability.BRCA1,一种参与维持基因组稳定性的“复杂”蛋白。
FEBS J. 2015 Feb;282(4):630-46. doi: 10.1111/febs.13150. Epub 2014 Dec 2.
8
The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers.抑癌基因 BRCA1/2、妇科和乳腺肿瘤的癌症易感性和基因组不稳定性。
Asian Pac J Cancer Prev. 2023 Sep 1;24(9):3139-3153. doi: 10.31557/APJCP.2023.24.9.3139.
9
BRCA1 in cancer, cell cycle and genomic stability.癌症、细胞周期与基因组稳定性中的乳腺癌1号基因(BRCA1)
Front Biosci. 2003 Sep 1;8:s1107-17. doi: 10.2741/1131.
10
Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.与波兰人群乳腺癌风险增加相关的BRCA1和BRCA2基因结构改变的分子诊断的选定方面
Hered Cancer Clin Pract. 2006 Aug 15;4(3):142-52. doi: 10.1186/1897-4287-4-3-142.

引用本文的文献

1
Case Report: Clinical impact of and vs. and germline double heterozygosity in ovarian cancer: a comparative case study.病例报告:卵巢癌中[具体基因1]和[具体基因2]与[另外两个具体基因]种系双杂合性的临床影响:一项对比病例研究。
Front Oncol. 2025 Jul 24;15:1614373. doi: 10.3389/fonc.2025.1614373. eCollection 2025.
2
Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review).与三阴性乳腺癌预后不良相关的分子靶点与治疗(综述)
Int J Oncol. 2025 Jun;66(6). doi: 10.3892/ijo.2025.5758. Epub 2025 May 30.
3
Novel Cyanopyrimidine Derivatives as Potential Anticancer Agents.

本文引用的文献

1
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.帕米帕利治疗伴有胚系 BRCA 突变的局部晚期或转移性人表皮生长因子受体 2 阴性乳腺癌患者的 II 期研究。
Breast Cancer Res Treat. 2023 Feb;197(3):489-501. doi: 10.1007/s10549-022-06785-z. Epub 2022 Dec 2.
2
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).Ceralasertib 介导的 ATR 抑制与奥拉帕利联合用于存在 DNA 损伤反应和修复改变的晚期癌症(奥拉帕利联合治疗)。
JCO Precis Oncol. 2021 Sep 7;5. doi: 10.1200/PO.20.00439. eCollection 2021.
3
新型氰基嘧啶衍生物作为潜在的抗癌药物。
Molecules. 2025 Mar 25;30(7):1453. doi: 10.3390/molecules30071453.
4
Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies.乳腺癌的分子亚型与机制:靶向治疗的精准医学方法
Cancers (Basel). 2025 Mar 25;17(7):1102. doi: 10.3390/cancers17071102.
5
Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapy.SMYD3-SHCBP1的致癌激活促进乳腺癌发展,并与免疫治疗耐药相关。
Cell Death Dis. 2025 Mar 29;16(1):220. doi: 10.1038/s41419-025-07570-8.
6
Genetic insights into idiopathic pulmonary fibrosis: a multi-omics approach to identify potential therapeutic targets.特发性肺纤维化的遗传学见解:一种用于识别潜在治疗靶点的多组学方法。
J Transl Med. 2025 Mar 16;23(1):337. doi: 10.1186/s12967-025-06368-8.
7
Signaling pathway dysregulation in breast cancer.乳腺癌中的信号通路失调
Oncotarget. 2025 Mar 13;16:168-201. doi: 10.18632/oncotarget.28701.
8
Pathogenic variants in and genes associated with female breast and ovarian cancer in the Mexican population.与墨西哥人群中女性乳腺癌和卵巢癌相关的基因中的致病变异。
J Med Life. 2025 Jan;18(1):38-47. doi: 10.25122/jml-2024-0213.
9
Pathogenic germline variants in cancer predisposition genes in patients with multiple primary cancers in an Asian population and the role of extended panel genetic testing.亚洲人群中多原发性癌症患者癌症易感基因的致病性种系变异及扩展基因检测面板的作用
ESMO Open. 2025 Mar;10(3):104495. doi: 10.1016/j.esmoop.2025.104495. Epub 2025 Mar 10.
10
Long Intergenic Non-Coding RNAs and in Breast Cancer Pathogenesis: Neighboring Companions or Nemeses?长链基因间非编码RNA与乳腺癌发病机制:是邻伴还是克星?
Noncoding RNA. 2025 Jan 29;11(1):9. doi: 10.3390/ncrna11010009.
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
BRCA1/2 基因突变型和野生型转移性乳腺癌患者中使用维利帕利联合替莫唑胺的 II 期临床试验。
Breast Cancer Res Treat. 2021 Oct;189(3):641-651. doi: 10.1007/s10549-021-06292-7. Epub 2021 Aug 20.
4
Targeting the DNA damage response in immuno-oncology: developments and opportunities.靶向免疫肿瘤学中的 DNA 损伤反应:进展与机遇。
Nat Rev Cancer. 2021 Nov;21(11):701-717. doi: 10.1038/s41568-021-00386-6. Epub 2021 Aug 10.
5
Niraparib for Advanced Breast Cancer with Germline and Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.尼拉帕利治疗种系和突变的晚期乳腺癌:EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO 研究。
Clin Cancer Res. 2021 Oct 15;27(20):5482-5491. doi: 10.1158/1078-0432.CCR-21-0310. Epub 2021 Jul 22.
6
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.奥拉帕利单药治疗真实世界中胚系 BRCA 突变、HER2 阴性转移性乳腺癌的临床疗效:IIIb 期 LUCY 期中分析。
Eur J Cancer. 2021 Jul;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub 2021 Jun 1.
7
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.奥拉帕利辅助治疗 - 或 - 突变型乳腺癌患者。
N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3.
8
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.Brca1 相关乳腺肿瘤发生的时间分辨单细胞分析显示管腔祖细胞的异常分化。
Nat Commun. 2021 Mar 9;12(1):1502. doi: 10.1038/s41467-021-21783-3.
9
Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.BRCA 基因突变携带者保乳联合治疗与乳房切除术的比较 - 系统评价和荟萃分析。
Breast. 2021 Apr;56:26-34. doi: 10.1016/j.breast.2021.02.001. Epub 2021 Feb 4.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.